Health
UniQure plans four-year clinical trial readout for Huntington gene therapy
STAT reports that UniQure is set to release four-year trial data for AMT-130 by late September.
The short version
- UniQure is expected to disclose four-year clinical trial results for its Huntington's disease gene therapy, AMT-130, before the end of September.[STAT]
- Prior three-year data released nearly one year ago showed a high dose administered to 12 patients slowed disease progression by 75% compared to natural history controls.[STAT]
- The forthcoming readout will provide updated long-term evidence on the experimental candidate's clinical performance.[STAT]
Key facts
- UniQure plans to release four-year clinical trial findings for AMT-130 before the end of September.[STAT]
- Earlier three-year data indicated that AMT-130 slowed Huntington's disease progression by 75% in 12 patients given a high dose relative to an external control group.[STAT]
- The initial three-year results were published approximately one year ago.[STAT]
What remains uncertain
- The upcoming four-year results have not yet been released, leaving the sustained safety and efficacy profile of AMT-130 unconfirmed.[STAT]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.